Spyre Therapeutics, Inc. - SYRE

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Aug 14, 2026 SCHEDULE 13G/A Perceptive Advisors LLC 4.9% 4,319,496 View
Aug 14, 2026 SCHEDULE 13G/A Joseph Edelman 4.9% 4,319,496 View
Aug 14, 2026 SCHEDULE 13G/A Perceptive Life Sciences Master Fund, Ltd. 4.9% 4,319,496 View
Aug 14, 2026 SCHEDULE 13G/A RTW Investments, LP 4.8% 4,251,996 View
Aug 14, 2026 SCHEDULE 13G/A Roderick Wong 4.8% 4,251,996 View
Jun 23, 2026 SCHEDULE 13D/A 9.99% View
Apr 22, 2026 SCHEDULE 13G Perceptive Advisors LLC 5.0% 4,319,496 View
Apr 22, 2026 SCHEDULE 13G Joseph Edelman 5.0% 4,319,496 View
Apr 22, 2026 SCHEDULE 13G Perceptive Life Sciences Master Fund, Ltd. 5.0% 4,319,496 View
Apr 20, 2026 SCHEDULE 13D/A 9.99% View
Mar 27, 2026 SCHEDULE 13G/A The Vanguard Group 0.0% 0 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.